Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × lortalamine × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Carboplatin 312 Paclitaxel 299 Cisplatin 249 Docetaxel 235 pembrolizumab 226 Gemcitabine 209 Pemetrexed 158 Capecitabine 145 Rituximab 143 Bevacizumab 139 Dexamethasone 122 Fluorouracil 116 Cyclophosphamide 102 Trastuzumab 100 Doxorubicin 96 Prednisone 91 Nivolumab 91 Oxaliplatin 86 atezolizumab 73 Leucovorin 70 durvalumab 68 130-nm albumin-bound paclitaxel 67 Injections 64 Lenalidomide 62 Irinotecan 57 Bortezomib 54 Letrozole 53 Fulvestrant 53 Topotecan 51 Drug Therapy 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡